BioNTech (NASDAQ:BNTX) Price Target Raised to $121.00 at JPMorgan Chase & Co.

Key Points

• JPMorgan Chase & Co. has increased its price target for BioNTech stock from $116.00 to $121.00, indicating a potential upside of 25.75% based on the company's current price.
• BioNTech's recent earnings report revealed a significant revenue growth of 102.6% year-over-year, with revenues reaching $306.46 million, although it missed EPS estimates.
• Currently, BioNTech holds a consensus rating of "Moderate Buy" from analysts, with a target price average of $134.56.

BioNTech (NASDAQ:BNTX - Free Report) had its price target boosted by JPMorgan Chase & Co. from $116.00 to $121.00 in a research note released on Monday,Benzinga reports. JPMorgan Chase & Co. currently has a neutral rating on the stock.

BNTX has been the topic of several other research reports. HC Wainwright restated a "buy" rating and issued a $136.00 price target on shares of BioNTech in a research note on Monday, September 8th. Bank of America lifted their price objective on shares of BioNTech from $126.00 to $134.00 and gave the company a "buy" rating in a report on Tuesday, August 5th. Wells Fargo & Company set a $150.00 price objective on shares of BioNTech and gave the company an "overweight" rating in a report on Tuesday, August 5th. Leerink Partners set a $112.00 price objective on shares of BioNTech in a research report on Monday, June 2nd. Finally, Truist Financial reiterated a "buy" rating and issued a $155.00 price objective (up previously from $151.00) on shares of BioNTech in a report on Tuesday, June 3rd. Eleven equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat, BioNTech currently has a consensus rating of "Moderate Buy" and an average price target of $134.56.

BioNTech Stock Performance

BNTX traded up $2.50 during trading on Monday, hitting $98.72. The stock had a trading volume of 741,522 shares, compared to its average volume of 1,323,409. The company has a 50 day moving average price of $107.10 and a 200-day moving average price of $103.31. The firm has a market cap of $23.73 billion, a price-to-earnings ratio of -61.70 and a beta of 1.39. BioNTech has a one year low of $81.20 and a one year high of $129.27. The company has a debt-to-equity ratio of 0.01, a current ratio of 8.61 and a quick ratio of 8.48.

BioNTech (NASDAQ:BNTX - Get Free Report) last issued its quarterly earnings results on Monday, August 4th. The company reported ($1.60) earnings per share for the quarter, missing the consensus estimate of ($1.41) by ($0.19). BioNTech had a negative net margin of 12.20% and a negative return on equity of 1.84%. The company had revenue of $306.46 million during the quarter, compared to analyst estimates of $161.26 million. During the same period in the previous year, the company posted ($3.36) EPS. The company's quarterly revenue was up 102.6% on a year-over-year basis. BioNTech has set its FY 2025 guidance at EPS. As a group, research analysts predict that BioNTech will post -3.88 EPS for the current year.

Institutional Investors Weigh In On BioNTech

Several large investors have recently made changes to their positions in the stock. Banque Cantonale Vaudoise bought a new position in BioNTech in the first quarter valued at about $36,000. LRI Investments LLC lifted its position in shares of BioNTech by 234.6% during the 2nd quarter. LRI Investments LLC now owns 445 shares of the company's stock valued at $47,000 after buying an additional 312 shares during the last quarter. Tower Research Capital LLC TRC raised its stake in shares of BioNTech by 118.2% during the 2nd quarter. Tower Research Capital LLC TRC now owns 563 shares of the company's stock valued at $60,000 after purchasing an additional 305 shares during the period. Hantz Financial Services Inc. increased its stake in BioNTech by 472.0% in the 2nd quarter. Hantz Financial Services Inc. now owns 572 shares of the company's stock worth $61,000 after acquiring an additional 472 shares during the last quarter. Finally, Banque Transatlantique SA bought a new position in shares of BioNTech during the 1st quarter valued at about $80,000. Institutional investors and hedge funds own 15.52% of the company's stock.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.